Our perspective aligns with emerging research in oncology that views cancer as a metabolic disease rooted in mitochondrial dysfunction, altered energy metabolism (e.g., the Warburg effect), and microenvironmental stressors like hypoxia. While chemotherapy and radiation remain standard treatments, their toxicity and long-term risks (e.g., secondary cancers, organ damage) are well-documented. Treating cancer as a metabolic disease offers a paradigm shift toward non-toxic, patient-centered care, but it is not a standalone cure. Combining metabolic strategies with judicious use of conventional therapies ( "metabolically supported" protocols) may improve outcomes while preserving quality of life. Below is a science-backed framework for addressing cancer through metabolic reprogramming.